Glaucoma addresses the diagnosis, monitoring, treatment, and prevention of progressive optic nerve damage associated with this major cause of irreversible vision loss. The session highlights advances in imaging, medical therapy, laser treatment, conventional surgery, minimally invasive procedures, risk assessment, neuroprotection, and long-term disease management.
Abstract Scope and Participation
Submissions may explore glaucoma mechanisms, diagnostics, imaging, medical treatments, surgical approaches, MIGS, disease progression, screening, adherence, outcomes, and novel therapeutic strategies. Glaucoma specialists, ophthalmologists, researchers, vision scientists, clinicians, and professionals developing diagnostic or therapeutic technologies are encouraged to participate.







Title : Lenadogene nolparvovec gene therapy in leber hereditary optic neuropathy
Magali Taiel, GenSight Biologics, France
Title : Stereotactic radiotherapy for wet age-related macular degeneration: year 4 results of a randomised, double-masked, sham-controlled trial
Tim Jackson, King’s College London, United Kingdom